CT-RD06

N/A

Report date: 2025/12/15 09:23:41

Base Information

Drug NameCT-RD06
Drug Alias NameCT-RD06RD06-03CTA-311
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Bioheng Biotech Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A